1. Opioid substitution in pregnancy a narrative review: contemporary evidence for use of methadone and buprenorphine in pregnancy.
- Author
-
Kinsella, M., Capel, Y., Nelson, S. M., and Kearns, R. J.
- Subjects
METHADONE treatment programs ,PREVENTION of drug side effects ,SUBSTANCE abuse in pregnancy ,GENERIC drug substitution ,BUPRENORPHINE ,CHILD development ,EVIDENCE-based medicine ,PREGNANCY outcomes ,HEALTH care teams ,OPIOID analgesics ,TERMINATION of treatment ,METHADONE hydrochloride ,INTEGRATED health care delivery ,PREGNANCY - Abstract
Illicit opioid use is a growing public health emergency and is associated with adverse medical and social outcomes. Opioid use in the pregnant population is increasing globally, and optimal management incorporates opioid substitution programs with improved concurrent engagement in medical care. The two main drugs used in opioid substitution programs are methadone and buprenorphine. Methadone has been used since the 1970s and provides treatment stability leading to improved engagement with obstetric services. Buprenorphine is a newer treatment, has greater dosing flexibility, and may be associated with fewer neonatal adverse effects. Direct comparisons of methadone and buprenorphine treatments are limited but suggest that buprenorphine is associated with less severe neonatal withdrawal; however, it is not universally well-tolerated and tends to be prescribed to less severely affected mothers. Given the lack of clear evidence to support one opioid substitution therapy over another, the principal aim of therapy should be to stabilize treatment and promote more comprehensive engagement with multidisciplinary services. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF